TY - JOUR T1 - c1 -酯酶抑制剂治疗抗体介导的肺移植术后排斥反应:两个案例报告JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.02027 -2019欧元SP - 1902027 AU - Parquin,弗朗索瓦•AU - Cuquemelle伊莉斯盟阵营,夏娃盟——Devaquet杰罗姆盟——Houllbracq菲利普斯马蒂尔德盟——圣人,爱德华盟——Brugiere Olivier AU -勒冈,摩根盟——Longchampt伊丽莎白AU - Malard,斯蒂芬妮AU -皮卡德,克莱门特AU -陶品,让吕克·非盟-面粉糊,安东尼盟,Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/early/2020/01/03/13993003.02027-2019.摘要肺移植(LTx)后N2 -抗体介导的排斥反应(AMR)与预后不良的[1]相关。最近，ISHLT建议对肺AMR[2]进行标准化分类。根据现有特征的数量，这些分类描述了AMR诊断的三种不同程度的确定性。然而，在缺乏真正的黄金标准的情况下，AMR的管理依赖于相当高的不确定性。该手稿最近已被《欧洲呼吸杂志》接受发表。在我们的制作团队进行编辑和排版之前，它以公认的形式在这里出版。当这些生产过程完成并且作者已经批准了结果证明之后，文章将转移到最新一期的在线ERJ。请打开或下载PDF阅读本文。利益冲突:帕尔昆博士没有什么要披露的。Conflict of interest: Dr Cuquemelle has nothing to disclose.Conflict of interest: Dr Camps has nothing to disclose.Conflict of interest: Dr Devaquet has nothing to disclose.Conflict of interest: Dr Sage has nothing to disclose.Conflict of interest: Dr Longchampt has nothing to disclose.Conflict of interest: Dr MALARD has nothing to disclose.Conflict of interest: Dr Picard has nothing to disclose.Conflict of interest: Dr taupin has nothing to disclose.Conflict of interest: Dr Roux has nothing to disclose.Conflict of interest: Dr Leguen has nothing to disclose.Conflict of interest: Dr Phillips-Houlbracq has nothing to disclose.Conflict of interest: Dr Brugiere has nothing to disclose. ER -